Ajanta Pharma launches anti-dementia drug in US

By: |
New Delhi | Published: June 14, 2016 12:56:54 PM

Ajanta Pharma today announced the launch of anti-dementia Memantine Hydrochloride tablets in the US market.

The US Food and Drug Administration (USFDA) has so far granted final approvals for 10 abbreviated new drug applications (ANDAs) and 2 tentative approvals, it said, adding that an additional 14 ANDAs are under review. (Reuters)The US Food and Drug Administration (USFDA) has so far granted final approvals for 10 abbreviated new drug applications (ANDAs) and 2 tentative approvals, it said, adding that an additional 14 ANDAs are under review. (Representative Photo: Reuters)

Ajanta Pharma today announced the launch of anti-dementia Memantine Hydrochloride tablets in the US market.

In a BSE filing, the company announced “the launch of Memantine Hydrochloride tablets in the US market through its wholly-owned subsidiary Ajanta Pharma USA Inc”.

Memantine Hydrochloride tablets is an anti-dementia drug and is a bio-equivalent to generic version of Namenda.

“The company has launched it in 2 strengths 5 mg and 10 mg tablets to address different levels of treatment,” it added.

The US Food and Drug Administration (USFDA) has so far granted final approvals for 10 abbreviated new drug applications (ANDAs) and 2 tentative approvals, it said, adding that an additional 14 ANDAs are under review.

Ajanta Pharma shares were trading 1.40 per cent up at Rs 1,583.05 on BSE in the morning session.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Next Stories
1Apple enhances Siri but still trails in artificial intelligence race
2India set to be top focus area as Microsoft buys LinkedIn for $26.2 bn
3Hit by bond default, Jyoti Structures may face ‘legal actions’